GS-1179
/ Gilead, Assembly Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
September 06, 2026
Safety and Tolerability of GS-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Interim Results from a Phase 1b Study
(IDWeek 2026)
- No abstract available
Clinical • P1 data • Infectious Disease
September 06, 2026
Efficacy and Virologic Analyses of GS-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Interim Results from a Phase 1b Study
(IDWeek 2026)
- No abstract available
Clinical • P1 data • Infectious Disease
September 06, 2026
Efficacy and Virologic Analyses of GS-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Interim Results from a Phase 1b Study
(IDWeek 2026)
- No abstract available
Clinical • P1 data • Infectious Disease
1 to 3
Of
3
Go to page
1